anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a stimulation emollient for skin mucous membrane which can alleviate the stimulation caused by surfactants by adding a trehalose monofatty acid ester thereto. SOLUTION: This emollient is obtained by formulating a trehalose monofatty acid ester of the formula (R is a 7-21C saturated or unsaturated straight-chain or side-chain-bearing acyl) to a preparation containing a surfactant. This emollient is added in an amount of 0.01-20wt.% based on the whole amount of a cosmetic. This emollient can be effectively formulated to the all types of surfactants, i.e., anionic, cationic, nonionic and amphoteric surfactants. The emollient is prepared in the form of a skin cleaner, hair shampoo, skin care agent, hair care agent, make-up cosmetic, a bathing medicine, permanent wave treatment agent, soap, kitchen cleaner, washing detergent and dentifrice. This emollient can largely improve the skin stimulation caused by surfactant without lowering the surface-activating function of the surfactant.
ASD is a neurodevelopmental disorder characterized by difficulties with social communication, limited and repetitive activities, and sensory sensitivity. The social, emotional, and behavioral issues that children with ASD face are a source of concern for their parents. Mental health issues such as stress, depression, and anxiety are common in these households. According to studies, mothers of children with ASD experience more stress and depression than mothers of children without ASD or mothers of children with other chronic disorders. Another aspect of having an ASD child that has an influence on health is fatigue. In terms of the health of parents of children with ASD, fatigue is often overlooked in study and practice. One of the study was investigated at the fatigue levels of 50 mothers of children with ASD who were between the ages of 2 and 5. Compared to mothers of healthy children, mothers of children with ASD reported higher fatigue, stress, worry, and depressive symptoms.

Participation in daily activities is critical for all children's healthy development, whether or not they have a disability. Participating in activities allows children to express themselves, find purpose, and improve their health. Exclusion and loneliness can arise from a child's inability to participate in normal childhood activities. This circumstance has a number of harmful consequences for the child. According to research, children with ASD participate in their home, school, and community surroundings at a considerably lower rate than their healthy peers, and this difference grows over time.

There is no study in the literature that examines the association between children with ASD's participation in home, school, and community environments, their parents' fatigue level, and the child's quality of life. As a result, the purpose of this research is to look at the relationship between ASD children's participation in home, school, and community settings and their parents' fatigue, depression, and quality of life, as well as the child's quality of life, by comparing them to a healthy control group.
Data streams are received from each of the plurality of sensors. These data streams comprise varying values generated by the sensors and characterize an associated physiological parameter. A parameter score is repeatedly determined for each physiological sensor that is based on whether the varying values for the associated physiological parameter deviate from at least one pre-defined threshold. A patient health index is repeatedly generated by combining each of the determined parameter scores to characterize an overall health of the patient. Data characterizing the patient health index is repeatedly provided. Related apparatus, systems, techniques and articles are also described.
Chemotherapy related anemia occurs in a majority of cancer patients and can cause impaired treatment outcomes, increased treatment-related complications and altered quality of life. Epoetin alfa administered on a weekly dosing schedule of 40,000 Units subcutaneously (\[SC\], under the skin) with dose adjustments based on hematologic response produces significant improvement in hemoglobin levels, decreased transfusion frequency and improved quality of life. It is unknown if the recently developed agent, darbepoetin alfa, administered on an every other week fixed dose will produce similar improvements in hematologic and quality of life outcomes. Thus, further randomization studies are warranted utilizing once weekly dosing (QW) of Epoetin alfa compared to once every other week (Q2W) darbepoetin alfa. Patients will receive study medications for up to 16 weeks.Safety \& efficacy evaluations will be performed at specified intervals throughout the study.The study hypothesis is that the Week 5 hemoglobin response rate in the Epoetin alfa group is better than that in the Darbepoetin alfa group. The starting dose for study drug is either Epoetin alfa (PROCRIT) 40,000 Units SC QW or Darbepoetin alfa (ARANESP) 200 mcg SC Q2W. Doses may be adjusted depending on the patient's hemoglobin levels up a maximum of 60,000 IU SC QW Epoetin alfa or 300 mcg SC Q2W Darbepoetin alfa.
The spleen plays a role in innate and adaptive immunity, and autoimmune diseases like rheumatoid arthritis (RA). We investigated the effect of splenectomy in early and moderate stages of autoimmune arthritis in a mouse model. To induce recombinant human G1-induced arthritis (GIA), BALB/c mice were immunized intraperitoneally three times in 4-week intervals with the rhG1 antigen. Mice were splenectomized on day 7 (SPE1) or day 35 (SPE2) after the initiation of immunization; tested for clinical severity, joint radiological and histological changes, serum levels of inflammatory cytokines and autoantibodies, and rhG1-specific immune responses; and compared to those in control mice with spleen left intact. Circulating Tregs and T-helper subset ratios in the spleen and inguinal lymph nodes (LNs) were also examined using flow cytometry. The onset of severe inflammatory response was significantly delayed in SPE1 and SPE2 groups compared to control mice at early stages of GIA, which was associated with increased circulating Tregs. After the third immunization, as disease progressed, the severity scores were robustly increased in all mice. Nevertheless, in splenectomized mice, we observed reduced joint deterioration and cartilage damage, more Th2 cells in LNs, and reduced levels of pro-inflammatory cytokines and autoantibodies in their sera. Mesenteric LN cells of splenectomized mice exhibited weaker response in vitro against the rhG1 antigen compared to control mice spleen. In conclusion, splenectomy in the early stages of GIA delayed the inflammatory response, suggesting a protective effect against the development and progression of severe destructive arthritis.
The design and structure of a fully automatic oxygen therapy apparatus is exhibited in this disclosure. The apparatus integrates a MEMS mass flow meter, an oximeter, a proportional valve and a smart liquid bottle. The control unit of the apparatus is embedded with a wireless communication device and powered by a battery pack. This apparatus is designed to replace the mechanical oxygen rotameter used in today's hospital or homecare oxygen therapy applications. With a set recipe or parameters locally or remotely, the disclosed apparatus can perform a fully automatic oxygen therapy for recovering the blood oxygen level of patient, without the frequent attention of the therapy administrator, and especially it significantly reduces the possibility of cross infection to the administrator during the attendance of the oxygen therapy process. The therapy process data are relayed to local users as well as a designated cloud or data center. This disclosure will be beneficial for both medical staffs and patient.
The group will consist of 100 patients (200 observations) receiving Gamma Knife treatment. Radiosurgery treatments will be re-planned using the convolution algorithm and compared to the TMR plans used to treat the patients.
AIM: Clinical risk scores for coronary artery disease (CAD) are used in clinical practice to select patients for diagnostic testing and therapy. Several studies have proposed that polygenic risk scores (PRSs) can improve the prediction of CAD, but the scores need to be validated in clinical populations with accurately characterized phenotypes. We assessed the predictive power of the three most promising PRSs for the prediction of coronary atherosclerosis and obstructive CAD.
METHODS: This study was conducted on 943 symptomatic patients with suspected CAD for whom the phenotype was accurately characterized using anatomic and functional imaging. Previously published genome-wide polygenic scores were generated to compare a genetic model based on PRSs with a model based on clinical data. The test and PRS cohorts were predominantly Caucasian of northern European ancestry.
RESULTS: All three PRSs predicted coronary atherosclerosis and obstructive CAD statistically significantly. The predictive accuracy of the models combining clinical data and different PRSs varied between 0.778 and 0.805 in terms of the area under the receiver operating characteristic (AUROC), being close to the model including only clinical variables (AUROC 0.769). The difference between the clinical model and combined clinical + PRS model was not significant for PRS1 (p=0.627) and PRS3 (p=0.061). Only PRS2 slightly improved the predictive power of the model (p=0.04). The likelihood ratios showed the very weak diagnostic power of all PRSs.
CONCLUSION: The addition of PRSs to conventional risk factors did not clinically significantly improve the predictive accuracy for either coronary atherosclerosis or obstructive CAD, showing that current PRSs are not justified for routine clinical use in CAD.
Subjects will receive 05 sessions of tDCS. The tDCS consist of application of current of 2 mA, the anode being placed in the motor cortex (M1) and the cathode in the supraorbital region, for 30 minutes,using electrodes with saline solution. The sham DIMST consist of the use of rubber electrodes placed in the same places that active treatment. Will use the same electrical apparatus, but without pass of current to the electrodes. The unit will be in front of the patient on with their lights blinking.
An endoscopic device is provided with an image capturing unit, an image processing unit, a plurality of line memories, and a display unit. The image capturing unit sequentially outputs line image signals, which are obtained by dividing the image of one frame into a plurality of rows extending along a first direction, in a second direction different from the first direction. The image processing unit subjects the line image signal to image processing. The line memories store the line image signals different from each other. The display unit is provided with, for each line memory, a display region for displaying an image formed by the line signal stored in one of the line memories. One or more line memories each store the line image signal subjected to the image processing by the image processing unit. The line memory which does not store the line signal subjected to the image processing stores the line image signal that is not subjected to the image processing by the image processing unit.
PURPOSE: To provide an angiotension conversion enzyme suppressor of non- peptide type and an anti-hypertensive medicine compsn. prepd. by using the same. CONSTITUTION: This anti-hypertensive medicine compsn. contains an effective amt. of flavonoid derivatives and pharmacologically permissible carriers and this suppressing compsn. is for angisotensin conversion enzyme. The dosage of the medicinal compsn. described above is preferably in a range of 10 to 20 mg/kg body weight in the case of oral administration per day per adult and a range of 0.5 to 5 mg/kg body weight in the case of the administration exclusive of the gastrointestinal tracts by injection. The examples of the flavonoid derivatives include the patsuletin-3,7-dimuranose glycoside of formula I, the patsuletin-3-O-rhamnosyl-7-O-[3-O-acetylrhamnose glycoside], chrynsosplenol-D of formula III, quercitrin of formula IV, the myricitrin of formula V, etc.
BACKGROUND: This study aimed to understand the vision health status of adolescents in the Western Pacific Region (WPR) using Global Burden of Disease (GBD) data from 1990 to 2019.
METHODS: We conducted a comprehensive analysis of blindness and vision loss using GBD data from 1990 to 2019, analyzed trends in the prevalence and burden of blindness and vision loss over time using joinpoint regression, and analyzed their independent effects on blindness and vision loss in three dimensions using age-period-cohort (APC) modeling.
RESULTS: The prevalence of blindness and vision loss among adolescents in the WPR showed an increasing trend between 1990 and 2019 (AAPC: 0.56%) and a slight increase in YLD (AAPC: 0.11%). The joinpoint regression showed a decreasing trend after 2017 (AAPC: -2.45%). The prevalence and burden trended downward in most Western Pacific countries, with only China rising significantly (AAPC prevalence: 0.57%). Refractive disorders had the highest prevalence among the subgroups. The risk of blindness and vision loss in adolescents reduced with age but grew later in time and at later birth. In addition, prevalence and burden were generally higher in females than males.
CONCLUSIONS: In the context of a declining global trend in the prevalence and burden of blindness and vision loss among adolescents, there is an increasing trend among adolescents in WPR, with the most pronounced rise in China. This finding has important implications for WPR, suggesting that more attention should be given to adolescent eye health in the region.
1343790 Cyanoacrylate adhesives JOHNSON & JOHNSON 10 June 1971 [11 June 1970] 19898/71 Heading C3P Cement compositions comprise a polymerizable monomeric cyanoacrylate ester of the formula CH 2  = C(CN)-CO-OR wherein R is C 1 -C 16  alkyl, cyclohexyl or phenyl; 1-4 parts by weight (per part of monomeric ester) of a finely divided filler; and from 5-25% by weight (based on the total cement composition) of finely divided sodium fluoride. Suitable fillers include fused silica, quartz, alumina and finely divided polyethylene, and preferably 25-75% by weight of the filler has particle sizes in the range 40-50 microns and 75-25% by weight 90-100 microns. The filler may contain an amine activator and can be stabilized against loss of activator activity by treating with triphenyl silane or a non-catalytic trialkoxysilyl compound. The sodium fluoride preferably has particle size in the range 10-100 microns. The compositions are particularly useful as dental cements and for this purpose can optionally be pigmented, e.g. with finely divided carbon. They are also suitable for filling or bonding materials such as ceramics, glass, metal, wood and rubber.
The invention discloses a polyacid Schiff base compound and its synthesis method and use. The polyacid Schiff base compound comprises methylimidazole counter cations and methylimidazole sandwich heteropoly acid fragments and belongs to a single crystal triclinic system. The polyacid Schiff base compound has a structural formula shown in the description. The synthesis method comprises putting an ammonium heptamolybdate solution in a container, dropwisely adding hydrochloric acid into the solution to obtain a solution a, dropwisely adding a new prepared methanol solution of [Mn(salpn)(H2O)]2(ClO4)2 into the solution a to obtain a solution b, carrying out microwave radiation heating for a reaction for 5-7min, carrying out cooling and filtration, sealing the filtrate through a film with pores, carrying out slow volatilization for 7-10 days to obtain blocky crystals, washing the blocky crystals through methanol and carrying out natural drying in air to obtain a desired product. The polyacid Schiff base compound is used in preparation of a drug for resisting cancers. In the novel compound synthesis, a final product is prepared under microwave radiation so that a compound yield is greatly improved. The monocrystalline structure provides novel data for a crystal database. A biological activity test proves that the polyacid fragments further improve antineoplastic effects of a Schiff base precursor.
This study will be conducted in patients with metastatic cancer and either moderate, severe or no hepatic impairment who have failed other antineoplastic therapies or for whom there is no standard therapy. The study will be conducted in two stages. Stage I will include patients with moderate hepatic impairment and Stage II will include patients with severe hepatic impairment. An analysis of data from the Stage I portion of the study will be performed to decide whether to enroll patients in the Stage II portion of the study. Patients with hepatic impairment (either moderate or severe) will be paired with matched control patients with normal hepatic function, matched on gender, age, and body surface are (BSA). Patients will receive a single dose of pixantrone on day 1 of a 21 day cycle. Blood samples will be obtained at various time points during the first week of the first cycle for pharmacokinetic (PK) analysis. If any patient with hepatic impairment develops a dose limiting toxicity, subsequent patients will be administered a lower dose of pixantrone. If any patient with hepatic impairment who is receiving the reduced dose of pixantrone experiences a dose limiting toxicity, the study will be terminated. Patients who demonstrate any clinical, radiologic, or other evidence of response or stabilization after the initial dose of pixantrone and who wish to continue treatment may do so at the discretion of the Investigator. Patients receiving additional cycles will be treated with pixantrone every 21 days for up to 5 additional cycles and will be followed for safety only, until 30 days after the last dose.
This invention relates to a moisture collagen protein face mask and its preparation method. This method is to extract the collagen protein from the fresh hogskin which is the functional material. It is made up of the 0.05-5% collagen protein, 0.2-10% cellulose derivant, the starch 0.05-10%, the moisture agent and the cross linker 1-20%. The process includes the reaction, the dry and forming. The face mask has not only the double moisture keeping efficient but good toughness, the ductility and adhesiveness; also it has the good feelness. So it is a good cosmetic.
PURPOSE:To obtain noncellular spherical silica, suitable as makeup cosmetics and excellent in monodispersity by dispersing cellular silica gel in a high- temperature gas, burning the silica gel and noncellulating the burned gel. CONSTITUTION:A cellular silica get is dispersed in a gas at 1000-2000 deg.C, burned and noncellulated. Thereby, noncellular spherical silica is produced. Noncellular silica, having a shape close to a true sphere and excellent in monodispersity is obtained according to the above-mentioned method. The resultant silica has low oil absorption. If the silica is blended in a makeup cosmetic, a soft cosmetic excellent in slip is obtained.
A method for segmenting bone in spectral image data is described herein. The spectral image data comprises at least a first set of image data corresponding to a first energy and a second set of image data corresponding to a second, different energy. The method comprises the following steps: obtaining the spectral image data. The method further includes extracting a set of features for each voxel in the spectral image data. The method further includes determining, for each voxel, a probability that each voxel represents a bone structure based on the set of features. The method further includes extracting bone structure from the spectral image data based on the probability.
PURPOSE:A drug composition having antithrombus action consisting essentially of 4-oxyimino-1-phenyl-1,2,3,4-tetrahydroquinoline or its halogen-substituted derivative at 6-position or its salt. CONSTITUTION:A preventive and remedy for arterial thrombosis consisting essentially of a compound shown by the formula (X is halogen or H) or its salt, having high safety. Showing more improved effect than aspirin, diphyridamole, ticlopidine, etc., capable of being medicated orally, through the intestine, or by injection. The compound shown by the formula, a main ingredient of the drug composition, is obtained by acylating diphenylamine with an acylating agent such as beta-propiolactone, etc., followed by subjecting the acylated compound to ring formation with an oxidizing agent such as phosphorus pentoxide, etc. The prepared compound is halogenated with an N-halogenosuccinimide, etc. and converted into an oxime with hydroxyamine, etc. to give a compound shown by the formula, a substituted derivative at 6-position.
The duration of the study is 4 years from the start of enrollment with at least 4 years of follow-up for each participant. The study is conducted in South Africa, Mali, and Mozambique with an expected enrollment target of 200 participants (as a minimum). In this study, newly diagnosed HIV-infected children will start ART as early as possible, following local standards of care, and will be followed up to 4 years of age. Clinical and blood data for viral load, immunology, and serology will be collected at the 11 visits. HIV reservoir size and HIV-specific immune responses will be analyzed at visit 1 and at 1, 2, 3, and 4 years after enrollment. We will identify children with HIV infection eligible to participate in proof-of-concept treatment/remission studies.

A predictive model developed from European participant data will help identify children with low reservoir. These predictions will then be compared with available data from participants already enrolled with an excellent control to refine the model.
A composition, system, articles and method for the enhancement of clotting in wounds with extravascular blood flow, especially where the surface of the tissue has been broken is described.  The system consists of biotolerable, porous particulates applied to the surface of a wound with liquid blood thereon. The porous nature of the particulate material, either free-flowing or packaged or restrained on or in a surface, enhances clotting. Chemical or biochemical agents, such as additional clotting agents, therapeutic agents, antibiotics, clot strengthening agents (such as fibrous structural materials), and the like may optionally be included on, with or within the porous particles. The particles may comprise such diverse materials as organics, metallics, inorganics, ceramics, and the like, both natural and artificial. It is generally preferred that the pore size distribution lies within a general range, and this range may vary from animal to animal and condition to condition, but generally falls within about 0.5 to 1000 micrometers or 3,000 to 200,000 Daltons.